Initial high dose chemotherapy plus autologous stem cell support improves survival outcomes compared with a standard CHOP regimen in people with higher intermediate risk aggressive lymphoma.
Glasmacher
Axel
A
Department of Internal Medicine, University of Bonn, Germany.